Literature DB >> 20818467

Evolving attitudes to Alzheimer's disease among the general public and caregivers in Europe: findings from the IMPACT survey.

M Wortmann1, S Andrieu, J Mackell, S Knox.   

Abstract

Understanding and appreciating the awareness of, and attitudes towards, Alzheimer's disease (AD) in the general public is of paramount importance to those charged with the development of health care policy. Furthermore, it is essential that this policy be formulated with consideration given to both the attitudes of the general population and to those within society more directly affected by AD; namely, the caregivers of patients with the disease. In the IMPACT survey, approximately 1000 members of the general public and 250 caregivers in 5 European countries (France, Germany, Italy, Spain, and the United Kingdom) completed a 30-minute, Web-based questionnaire. In this article, we compare and contrast the attitudes and opinions of these populations in an attempt to define specific themes. Indeed, caregivers were more concerned about consequences of growing old and were more fearful of AD than general public respondents, although a high proportion in both groups acknowledged the significant impact of the disease. Similarly, although most respondents in the 2 groups recognised that early signs and symptoms of AD are difficult to detect, caregivers were more skeptical of the abilities of both primary physicians and specialists to detect these early signs and symptoms. In terms of treatment, caregivers were less convinced of the effectiveness of treatment beyond the early stages of AD and more likely to agree that current treatments are associated with side effects. Respondents in both groups had a negative view of their government's investment in AD, but caregivers, particularly those in France, Spain and the United Kingdom, were more likely to feel that their government acts as a barrier to treatment. Some survey respondents from the 2 groups also had a negative view of their governments' attempts to raise awareness of AD and make its treatment a high priority. Overall, comparison of responses from these 2 groups suggests that caregivers' personal experiences of AD profoundly affect their attitudes and perceptions surrounding the disease.

Entities:  

Mesh:

Year:  2010        PMID: 20818467     DOI: 10.1007/s12603-010-0264-x

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  14 in total

1.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Authors:  H Feldman; S Gauthier; J Hecker; B Vellas; P Subbiah; E Whalen
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

2.  Assessing attitudes and behaviours surrounding Alzheimer's disease in Europe: key findings of the Important Perspectives on Alzheimer's Care and Treatment (IMPACT) survey.

Authors:  R W Jones; J Mackell; K Berthet; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

3.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Authors:  R C Mohs; R S Doody; J C Morris; J R Ieni; S L Rogers; C A Perdomo; R D Pratt
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

4.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

5.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

6.  Diagnosis of dementia in primary care: a representative survey of family physicians and neuropsychiatrists in Germany.

Authors:  Gabriela Stoppe; Sebastian Haak; Anita Knoblauch; Lienhard Maeck
Journal:  Dement Geriatr Cogn Disord       Date:  2007-02-09       Impact factor: 2.959

7.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

8.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

Review 9.  Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

Authors:  I A Lockhart; S A Mitchell; S Kelly
Journal:  Dement Geriatr Cogn Disord       Date:  2009-11-06       Impact factor: 2.959

10.  Diagnosing cognitive impairment and dementia in primary health care -- a more active approach is needed.

Authors:  Minna Löppönen; Ismo Räihä; Raimo Isoaho; Tero Vahlberg; Sirkka-Liisa Kivelä
Journal:  Age Ageing       Date:  2003-11       Impact factor: 10.668

View more
  8 in total

1.  Recruitment, retention and other methodological issues related to clinical trials for Alzheimer's disease.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

2.  The time has arrived to meet the challenge of Alzheimer's disease in Europe.

Authors:  R W Jones
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

3.  Perception of Alzheimer's disease in the French population.

Authors:  A Breining; B Lavallart; S Pin; C Léon; S Moulias; P Arwidson; F Beck; C Berr; M Verny
Journal:  J Nutr Health Aging       Date:  2014-04       Impact factor: 4.075

4.  Clinical practice patterns of generalists and specialists in Alzheimer's disease: what are the differences, and what difference do they make?

Authors:  L Robinson; B Vellas; S Knox; K Lins
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

5.  Assessing physician attitudes and perceptions of Alzheimer's disease across Europe.

Authors:  P Martinez-Lage; L Frolich; S Knox; K Berthet
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

6.  Physicians and caregivers: ready and waiting for increased participation in clinical research.

Authors:  R W Jones; S Andrieu; S Knox; J Mackell
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

7.  What Does the Australian General Public Know About Treatments for Dementia? A Population Survey.

Authors:  Miia Rahja; Kate Laver; Tracy Comans; Maria Crotty
Journal:  Gerontol Geriatr Med       Date:  2018-08-13

8.  Sharing knowledge to advance healthcare policies in Europe for people living with dementia and their carers: the ALCOVE project.

Authors:  Christine Barr; Nathalie Riolacci-Dhoyen; Maggie Galbraith; Armelle Leperre-Desplanques
Journal:  Arch Public Health       Date:  2012-08-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.